Glancy Binkow & Goldberg Reminds Investors of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Aegerion Pharmaceuticals, Inc.

Business Wire

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP reminds investors that all purchasers of Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (AEGR) securities between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”), have until March 17, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at shareholders@glancylaw.com to discuss this matter or other potential claims if you are a long-term shareholder of Aegerion.

Aegerion’s cholesterol drug, Juxtapid, is marketed in the United States to treat patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disease that impairs the function of the receptor responsible for removing LDL-C or “bad” cholesterol from the blood. The Complaint, filed in the United States District Court for the District of Massachusetts, alleges that the defendants made false and misleading statements or failed to disclose that Aegerion’s marketing practices during the Class Period were in violation of the Food, Drug, and Cosmetic Act and, as a result, the Company faced heightened regulatory scrutiny by the Food and Drug Administration and other governmental bodies.

To learn more about this action or if you have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:
Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340
shareholders@glancylaw.com
www.glancylaw.com

Rates

View Comments (0)